Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ).
Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, has announced a significant purchase order for its FebriDx test from iMedical, Inc., marking the largest single order since the test’s launch. This order underscores the growing acceptance and demand for FebriDx in the US market, following its FDA clearance in July 2023 for aiding in the diagnosis of bacterial acute respiratory infections. The collaboration with iMedical, a company known for providing cost-saving solutions to healthcare facilities, is expected to enhance the market presence of FebriDx and improve health outcomes through advanced point-of-care technology.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. The company offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.
Average Trading Volume: 1,354,925
Technical Sentiment Signal: Sell
Current Market Cap: A$20.96M
Find detailed analytics on LDX stock on TipRanks’ Stock Analysis page.